FDA Adverse Event Death Summary report: N

MELODY TRANSCATHETER PULMONARY VALVE

MDR report key: 16456203 · Received February 28, 2023

Report

Report Number
2025587-2023-00730
Event Type
Death
Date Received
February 28, 2023
Date of Event
October 26, 2022
Report Date
February 28, 2023
Manufacturer
MEDTRONIC HEART VALVES DIVISION
Product Code
NPV
PMA / PMN Number
P140017
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
AS
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

CITATION: LAWLEY C.; ET AL. TEN YEARS OF PERCUTANEOUS PULMONARY VALVE IMPLANTATION IN AUSTRALIA AND NEW ZEALAND. HEART LUNG CIRC. 2022 DEC;31(12):1649-1657. DOI: 10.1016/J.HLC.2022.07.008. EPUB 2022 AUG 26. PMID: (B)(4) EARLIEST DATE OF PUBLICATION USED FOR DATE OF EVENT AND DATE OF DEATH. MEDTRONIC PRODUCTS REFERENCED: CONTEGRA (PMA# H020003, PRODUCT CODE: MWH); HANCOCK (PMA# P980043, PRODUCT CODE: DYE); MOSAIC (PMA# P990064, PRODUCT CODE: DYE); FREESTYLE (PMA# P970031, PRODUCT CODE: LWR); MELODY (PMA# P140017, PRODUCT CODE: NPV). EARLIEST APPROVED PRODUCT USED FOR PRODUCT CODE AND PMA#. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. WITHOUT RETURN OF THE PRODUCT NO DEFINITIVE CONCLUSION CAN BE MADE REGARDING THE CLINICAL OBSERVATIONS. SELECT PATIENT INFORMATION CANNOT BE INCLUDED IN REGULATORY REPORT DUE TO REGIONAL PRIVACY REGULATIONS. MEDTRONIC IS SUBMITTING THIS REPORT TO COMPLY WITH FDA REPORTING REGULATIONS UNDER 21 CFR PARTS 4 AND 803. THIS REPORT IS BASED UPON INFORMATION OBTAINED BY MEDTRONIC, WHICH THE COMPANY MAY NOT HAVE BEEN ABLE TO FULLY INVESTIGATE OR VERIFY PRIOR TO THE DATE THE REPORT WAS REQUIRED BY THE FDA. MEDTRONIC HAS MADE REASONABLE EFFORTS TO OBTAIN MORE COMPLETE INFORMATION AND HAS PROVIDED AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. IN PARTICULAR, THIS REPORT DOES NOT CONSTITUTE AN ADMISSION BY ANYONE THAT THE PRODUCT DESCRIBED IN THIS REPORT HAS ANY ¿DEFECTS¿ OR HAS ¿MALFUNCTIONED¿. THESE WORDS ARE INCLUDED IN THE FDA 3500A FORM AND ARE FIXED ITEMS FOR SELECTION CREATED BY THE FDA TO CATEGORIZE THE TYPE OF EVENT SOLELY FOR THE PURPOSE OF REGULATORY REPORTING. MEDTRONIC OBJECTS TO THE USE OF THESE WORDS AND OTHERS LIKE THEM BECAUSE OF THE LACK OF DEFINITION AND THE CONNOTATIONS IMPLIED BY THESE TERMS. THIS STATEMENT SHOULD BE INCLUDED WITH ANY INFORMATION OR REPORT DISCLOSED TO THE PUBLIC UNDER THE FREEDOM OF INFORMATION ACT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. A GOOD FAITH EFFORT WILL BE MADE TO OBTAIN THE APPLICABLE INFORMATION RELEVANT TO THE REPORT. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 0

LITERATURE WAS REVIEWED REGARDING A MULTI-CENTER LONGITUDINAL STUDY ON PERCUTANEOUS PULMONARY VALVE IMPLANTATION (PPVI) IN AUSTRALIA AND NEW ZEALAND. THE PATIENTS UNDERWENT PPVI DUE TO PULMONARY TRACT BIOPROSTHETIC/HOMOGRAFT ISOLATED OR MIXED STENOSIS AND REGURGITATION. THE AUTHORS DESCRIBED PATIENT DEATHS DUE TO PULMONARY HOMOGRAFT RUPTURE, CARDIAC ARREST SECONDARY TO HEMO PERICARDIAL TAMPONADE, CARDIAC ARREST SECONDARY TO PULMONARY BLOOD FLOW OCCLUSION FROM VALVE MIGRATION AND FROM HEART FAILURE RELATED TO REFRACTORY INFECTIVE ENDOCARDITIS (IE). THE STATUS OF THE DEVICES IS UNKNOWN.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
85969 MELODY TRANSCATHETER PULMONARY VALVE PULMONARY VALVE PROSTHESIS PERCUTANEOUSLY DELI NPV MEDTRONIC HEART VALVES DIVISION PB 10

Patients

Seq Age Sex Outcome Treatment
1 19 YR Male Death UNKNOWN IPG.